Replies to post #162068 on Biotech Values

[DewDiligence]

Because Otamixaban still has potential as an alternative to Coumadin for complications from atrial fib.

No—SNY is discontinuing Otamixaban for all indications (http://en.sanofi.com/Images/33127_20130603_rdupdate_en.pdf ).